XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.2

Description of Business - Additional Information (Details) - Metacrine, Inc. [Member] - Metacrine's FXR Program [Member]	12 Months Ended
	Mar. 31, 2023 Compounds
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Number of clinically tested compounds	2
Number of discovery or preclinical compounds	2,000

X

- Definition

Description of business and summary of significant accounting policies.

+ References

No definition available.

+ Details

Name:	onvo_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix:	onvo_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of clinically tested compounds.

+ References

No definition available.

+ Details

Name:	onvo_NumberOfClinicallyTestedCompounds
Namespace Prefix:	onvo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of discovery or preclinical compounds.

+ References

No definition available.

+ Details

Name:	onvo_NumberOfDiscoveryOrPreclinicalCompounds
Namespace Prefix:	onvo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=onvo_MetacrineIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=onvo_MetacrinesFxrProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: